A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures

Trial Profile

A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Partial epilepsies; Tuberous sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXIST-3
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2017 The trial has been completed in Denmark.
    • 28 Apr 2017 Results assessing efficacy and safety presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of post hoc analysis examining the psychometricproperties of three age specific QoL measures presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top